Capital Fund Management (CFM)’s AbbVie ABBV Stock Holding History

Capital Fund Management (CFM)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.26M	Sell	10,400 -74,400	-88%	-$16.5M	0.01%	1297
2025 Q4	$19.4M	Buy	84,800 +13,500	+19%	+$3.08M	0.05%	505
2025 Q3	$16.5M	Sell	71,300 -28,100	-28%	-$5.72M	0.04%	600
2025 Q2	$18.5M	Sell	99,400 -22,200	-18%	-$4.13M	0.05%	492
2025 Q1	$25.5M	Buy	121,600 +29,600	+32%	+$5.75M	0.07%	365
2024 Q4	$16.3M	Sell	92,000 -39,900	-30%	-$7.34M	0.04%	547
2024 Q3	$26M	Sell	131,900 -256,000	-66%	-$47.8M	0.07%	369
2024 Q2	$66.5M	Sell	387,900 -4,300	-1%	-$712K	0.2%	136
2024 Q1	$71.4M	Buy	392,200 +305,700	+353%	+$52.7M	0.21%	125
2023 Q4	$13.4M	Sell	86,500 -235,900	-73%	-$34.4M	0.04%	628
2023 Q3	$48.1M	Buy	322,400 +16,900	+6%	+$2.48M	0.17%	154
2023 Q2	$41.2M	Buy	305,500 +271,300	+793%	+$39.8M	0.17%	161
2023 Q1	$5.45M	Sell	34,200 -86,700	-72%	-$13.3M	0.03%	706
2022 Q4	$19.5M	Sell	120,900 -216,900	-64%	-$33.3M	0.13%	203
2022 Q3	$45.3M	Buy	337,800 +11,700	+4%	+$1.68M	0.36%	60
2022 Q2	$49.9M	Buy	326,100 +178,800	+121%	+$27.3M	0.45%	31
2022 Q1	$23.9M	Buy	+147,300	New	+$21.4M	0.2%	131
2021 Q2	–	Sell	-196,100	Closed	-$21.2M	–	1392
2021 Q1	$21.2M	Sell	196,100 -52,272	-21%	-$5.59M	0.23%	116
2020 Q4	$26.6M	Sell	248,372 -112,364	-31%	-$10.8M	0.25%	96
2020 Q3	$31.6M	Sell	360,736 -18,532	-5%	-$1.74M	0.39%	55
2020 Q2	$37.2M	Buy	379,268 +201,268	+113%	+$17.7M	0.59%	22
2020 Q1	$13.6M	Buy	178,000 +46,500	+35%	+$3.96M	0.21%	142
2019 Q4	$11.6M	Buy	131,500 +110,700	+532%	+$9.19M	0.09%	275
2019 Q3	$1.57M	Sell	20,800 -104,700	-83%	-$7.18M	0.01%	865
2019 Q2	$9.13M	Buy	125,500 +23,500	+23%	+$1.85M	0.08%	324
2019 Q1	$8.22M	Sell	102,000 -195,600	-66%	-$16M	0.07%	349
2018 Q4	$27.4M	Sell	297,600 -38,700	-12%	-$3.4M	0.24%	93
2018 Q3	$31.8M	Sell	336,300 -366,500	-52%	-$34.8M	0.17%	141
2018 Q2	$65.1M	Sell	702,800 -355,700	-34%	-$34.7M	0.34%	54
2018 Q1	$100M	Sell	1,058,500 -227,400	-18%	-$25M	0.6%	8
2017 Q4	$124M	Buy	1,285,900 +783,300	+156%	+$73.8M	0.69%	13
2017 Q3	$44.7M	Buy	502,600 +346,600	+222%	+$26.4M	0.32%	75
2017 Q2	$11.3M	Buy	156,000 +137,200	+730%	+$9.22M	0.09%	273
2017 Q1	$1.23M	Sell	18,800 -559,200	-97%	-$35.2M	0.01%	861
2016 Q4	$36.2M	Buy	578,000 +464,900	+411%	+$28.4M	0.31%	81
2016 Q3	$7.13M	Sell	113,100 -104,300	-48%	-$6.75M	0.07%	354
2016 Q2	$13.5M	Sell	217,400 -102,100	-32%	-$6.22M	0.13%	201
2016 Q1	$18.3M	Sell	319,500 -307,500	-49%	-$17.1M	0.18%	148
2015 Q4	$37.1M	Buy	627,000 +409,300	+188%	+$23.6M	0.38%	48
2015 Q3	$11.8M	Buy	217,700 +45,200	+26%	+$2.94M	0.13%	200
2015 Q2	$11.6M	Sell	172,500 -12,900	-7%	-$842K	0.15%	188
2015 Q1	$10.9M	Buy	185,400 +93,900	+103%	+$5.67M	0.15%	180
2014 Q4	$5.99M	Buy	91,500 +49,300	+117%	+$3.11M	0.07%	381
2014 Q3	$2.44M	Buy	42,200 +25,300	+150%	+$1.4M	0.03%	621
2014 Q2	$954K	Buy	+16,900	New	+$887K	0.01%	983

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Fund Management (CFM)'s ABBV Position: Q1 2026 in Review

Capital Fund Management (CFM) sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 22,088 shares — an estimated $4.9M sold.

Capital Fund Management (CFM) first reported a position in ABBV in Q2 2014 and held it in 28 quarters. The position peaked at $139M in Q3 2018. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Capital Fund Management (CFM) reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Capital Fund Management (CFM) sold 22,088 AbbVie shares in Q1 2026, an estimated $4.9M.
Capital Fund Management (CFM) first reported a position in AbbVie in Q2 2014 and held it in 28 quarters.
Capital Fund Management (CFM)'s AbbVie position peaked at $139M in Q3 2018.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q1 2026, filed 14 May 2026.